Vericel develops, manufactures, and markets autologous cell-based therapies for patients with serious diseases and conditions. The Company markets two cell therapy products in the United States. Carticel (autologous cultured chondrocytes) is an autologous chondrocyte implant intended to treat cartilage defects in the knee in patients who have had an inadequate response to a prior arthroscopic or other surgical repair procedure. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel is also developing 2 additional cell products. MACI is a third generation autologous chondrocyte implant intended to treat cartilage defects in the knee. Ixmyelocel-T is a multicellular therapy intended to treat advanced heart failure due to ischemic dilated cardiomyopathy (DCM).
Type | Public | |
Founded | 1989 | |
HQ | Cambridge, MA, US | Map |
Website | vcel.com | |
Employee Ratings | More |
USD | |
---|---|
Revenue (Q3, 2020) | 32.3m |
Gross profit (Q3, 2020) | 22.5m |
Gross profit margin (Q3, 2020), % | 69.7% |
Net income (Q3, 2020) | 3.6m |
EBIT (Q3, 2020) | 3.5m |
Market capitalization (8-Feb-2021) | 2.3b |
Closing stock price (8-Feb-2021) | 49.7 |
Cash (30-Sept-2020) | 43.5m |
EV | 2.2b |
USD | Q2, 2011 | Q3, 2011 | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 9.0k | 2.0k | 8.0k | 3.0k | 4.4m | 9.7m | 10.8m | 13.6m | 11.3m | 14.1m | 12.8m | 10.9m | 9.4m | 17.0m | 14.3m | 18.0m | 19.0m | 22.5m | 22.0k | 26.2m | 30.5m | 26.7m | 20.0m | 32.3m | |||||
Cost of goods sold | 2.0k | 2.0k | 2.0k | 1.0k | 5.0m | 5.5m | 5.6m | 6.9m | 6.8m | 6.6m | 7.3m | 6.9m | 7.1m | 7.7m | 7.2m | 7.7m | 9.9m | 8.7m | 9.8m | ||||||||||
Gross profit | 7.0k | 6.0k | 2.0k | (577.0k) | 4.1m | 5.3m | 6.7m | 4.5m | 7.5m | 5.5m | 4.1m | 2.3m | 9.3m | 7.1m | 10.4m | 16.8m | 11.4m | 22.5m | |||||||||||
Gross profit Margin, % | 78% | 75% | 67% | (13%) | 43% | 49% | 49% | 40% | 54% | 43% | 37% | 24% | 55% | 50% | 57% | 63% | 57% | 70% |
USD | Q2, 2011 | Q3, 2011 | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 18.5m | 11.9m | 36.7m | 28.7m | 21.1m | 9.2m | 4.5m | 10.8m | 8.8m | 7.3m | 37.6m | 25.9m | 20.2m | 18.7m | 13.5m | 9.8m | 8.9m | 19.8m | 14.0m | 15.5m | 29.8m | 95.0m | 53.3m | 35.1m | 14.0m | 36.9m | 45.6m | 55.7m | 43.5m |
Accounts Receivable | 9.0k | 11.0k | 9.0k | 9.0k | 4.3m | 4.0m | 9.2m | 9.0m | 7.6m | 9.7m | 9.0m | 7.9m | 12.1m | 14.7m | 15.4m | 13.2m | 17.5m | 15.5m | 18.8m | 21.1m | 20.0m | 24.2m | 23.7m | 26.2m | |||||
Prepaid Expenses | 524.0k | 622.0k | 453.0k | 455.0k | 364.0k | 300.0k | 236.0k | 545.0k | 400.0k | 610.0k | 1.5m | 845.0k | 2.3m | 514.0k | 662.0k | 1.0m | 741.0k | 1.0m | 1.1m | 1.4m | 1.4m | 1.3m | 2.3m | 2.7m | 2.2m | 3.3m | |||
Inventories | 1.9m | 1.7m | 2.0m | 2.1m | 1.6m | 1.9m | 2.4m | 3.6m | 4.0m | 3.2m | 4.0m | 3.9m | 3.7m | 3.6m | 4.1m | 4.8m | 6.8m | 7.3m | 8.4m | 10.1m |
USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|---|---|---|---|---|---|
Net Income | (19.7m) | (29.5m) | (15.6m) | (19.9m) | (16.3m) | (19.6m) | (17.3m) | (8.1m) | |
Depreciation and Amortization | 647.0k | 649.0k | 489.0k | 752.0k | 1.6m | 1.9m | 1.6m | 1.4m | 1.7m |
Inventories | 119.0k | (86.0k) | (2.2m) | (657.0k) | 235.0k | (3.3m) | |||
Accounts Payable | 63.0k | 284.0k | (571.0k) | 2.8m | 1.7m | (1.1m) | (1.4m) | 899.0k | (1.0m) |
USD | Q2, 2011 | Q3, 2011 | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (14.9m) | (16.9m) | (9.5m) | (16.8m) | (22.8m) | (5.5m) | (10.4m) | (12.7m) | (6.0m) | (10.6m) | (17.5m) | (4.9m) | (7.0m) | (11.4m) | (3.6m) | (6.7m) | (13.4m) | (9.8m) | (12.2m) | (17.6m) | (7.7m) | (12.3m) | (13.4m) | (2.8m) | (13.0m) | (9.4m) | |||
Depreciation and Amortization | 296.0k | 464.0k | 179.0k | 341.0k | 487.0k | 150.0k | 275.0k | 387.0k | 97.0k | 246.0k | 496.0k | 328.0k | 672.0k | 1.2m | 445.0k | 923.0k | 1.4m | 409.0k | 784.0k | 1.2m | 427.0k | 813.0k | 1.1m | 324.0k | 698.0k | 1.2m | 533.0k | 1.1m | 1.6m |
Inventories | (1.0k) | 278.0k | 489.0k | (85.0k) | (157.0k) | (339.0k) | (580.0k) | (1.1m) | (2.3m) | (563.0k) | 173.0k | (793.0k) | (18.0k) | 302.0k | (148.0k) | (505.0k) | (1.2m) | (3.3m) | (466.0k) | (1.6m) | (3.3m) | ||||||||
Accounts Payable | (436.0k) | (452.0k) | 421.0k | 821.0k | 281.0k | (232.0k) | 87.0k | (329.0k) | (201.0k) | 4.6m | (69.0k) | 460.0k | (412.0k) | (899.0k) | (2.0m) | (2.3m) | (2.2m) | (300.0k) | (404.0k) | (1.1m) | (229.0k) | (1.0m) | (1.2m) | (1.4m) | (2.2m) | (1.9m) | (59.0k) | (1.7m) | (52.0k) |
USD | Q2, 2011 |
---|---|
Financial Leverage | -2 x |
FY, 2016 | |
---|---|
Approval Phase Products | 3 |
Phase II Trials Products | 1 |
When was Vericel founded?
Vericel was founded in 1989.
Who are Vericel key executives?
Vericel's key executives are Dominick Colangelo, Mike Halpin and Joe Mara.
How many employees does Vericel have?
Vericel has 241 employees.
What is Vericel revenue?
Latest Vericel annual revenue is $117.9 m.
What is Vericel revenue per employee?
Latest Vericel revenue per employee is $489 k.
Who are Vericel competitors?
Competitors of Vericel include MODAG, Fratagene Therapeutics and Clover Biopharmaceuticals.
Where is Vericel headquarters?
Vericel headquarters is located at 64 Sidney St, Cambridge.
Where are Vericel offices?
Vericel has offices in Cambridge and Ann Arbor.
How many offices does Vericel have?
Vericel has 2 offices.
Receive alerts for 300+ data fields across thousands of companies